<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820092</url>
  </required_header>
  <id_info>
    <org_study_id>Xerecept: CPDS 0805</org_study_id>
    <nct_id>NCT00820092</nct_id>
  </id_info>
  <brief_title>Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers</brief_title>
  <official_title>A Phase 1,Dose Escalation Study to Compare the Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Profiles of the 24-hour Intravenous Administration of Xerecept in Healthy Japanese and Caucasian Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celtic Pharma Development Services</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celtic Pharma Development Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To investigate the safety and tolerability of Xerecept during and following a 24-hour
           intravenous administration to healthy Japanese to healthy Japanese and Caucasian
           subjects

        2. To compare the PK profile of hCRF during and following a 24-hour intravenous Xerecept
           administration between healthy Japanese and Caucasian subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      none needed
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of AEs Clinical laboratory tests( chemistry,hematology,urinalysis) Physical exam and vital signs ECG AUC, Tmax Cmax Terminal half life AUC for cortisol concentration</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Edema</condition>
  <arm_group>
    <arm_group_label>Xerecept 1.0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 ug/kg/hr hCRF -24 hour IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xerecept 2.0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.0 ug/kg/hr-24 hour IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xerecept 3.0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.0 ug/kg/hr-24 hour infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xerecept 1.0</intervention_name>
    <description>24 hour infusion</description>
    <arm_group_label>Xerecept 1.0</arm_group_label>
    <other_name>hCRF infusion</other_name>
    <other_name>1.0 ug/kg/hr</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xerecept 2.0</intervention_name>
    <description>24 hour infusion</description>
    <arm_group_label>Xerecept 2.0</arm_group_label>
    <other_name>hCRF infusion</other_name>
    <other_name>2.0 ug/kg/hr</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xerecept 3.0</intervention_name>
    <description>24 hour infusion</description>
    <arm_group_label>Xerecept 3.0</arm_group_label>
    <other_name>hCRF infusion</other_name>
    <other_name>3.0 ug/kg/hr</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female Japanese subjects who are citizens of Japan

          -  Healthy male and female Caucasian subjects

          -  Age range 20-45 years

          -  BMI &gt;19 and &lt;27 kg/m squared

        Exclusion Criteria:

          -  Female subjects must not be pregnant at the time of study and use adequate birth
             control methods before,during and 4 weeks after the study

          -  Subjects must be negative for HCV and HIV

          -  Subjects must have negative urine tests for drugs of abuse and alcohol at screening

          -  Subjects must not have any clinically significant medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <last_update_submitted>July 29, 2013</last_update_submitted>
  <last_update_submitted_qc>July 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xerecept</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Japanese versus Caucasians</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

